Greater Philadelphia has the science, talent, and infrastructure to rival any biotech hub in the United States. It has the universities that produce breakthroughs, the hospitals that turn discoveries into treatments, and a workforce that has fueled a thriving cell and gene therapy sector. But in biotechnology, science alone doesn’t guarantee success — capital does. And it’s here that Philadelphia continues to fall short.
That shortfall was highlighted again in the latest Genetic Engineering & Biotechnology News (GEN) ranking of the top U.S. biopharma clusters. In its 2025 list, GEN placed Philadelphia seventh nationally, down one spot from last year. For the first time, Los Angeles/Orange County — a region that has rapidly climbed the ranks on the strength of venture investment — overtook Philadelphia.
The rankings offer both a snapshot of where clusters stand and a reminder of what it takes to remain competitive. While Philadelphia continues to perform strongly in most categories, from patents and NIH funding to lab space and jobs, it is falling behind in the one area that powers everything else: venture capital.
Strong Science, Weak Capital
GEN’s methodology weighs several factors, including venture capital, NIH funding, patents, lab space, and employment. Philadelphia’s numbers in 2024 were impressive across four of those five categories. The region ranked fifth in patents, with 16,484 active families. It ranked sixth in NIH funding, attracting $2.065 billion. It also placed sixth in both lab space (24.5 million square feet) and life sciences employment, with more than 88,000 jobs.
Those measures confirm what many in the industry already know: Philadelphia is producing science at a world-class level and building the infrastructure to support it. But the region’s venture capital totals tell a different story. Philadelphia companies raised $656 million in 2024, which placed ninth among the ten clusters ranked. In the first half of 2025, that figure was just $236 million — a slow start compared to competitor regions.
The contrast with the top clusters is stark. Boston and San Francisco each routinely raise between $5 billion and $7 billion annually. Even Los Angeles, which overtook Philadelphia this year, raised more than twice Philadelphia’s total in 2024. The gap is not just wide — it is widening.
“Venture capital is more than just one category in the rankings — it’s the fuel that powers biotech growth,” GEN’s report noted. That fuel, the report emphasized, is what allows discoveries to become companies, and companies to scale into global players. Without it, even the strongest science can struggle to reach patients.
Why Venture Capital Matters
The rankings underscore a hard truth: in biotech, science and capital are inseparable. While patents, NIH grants, and research infrastructure are essential, they cannot substitute for the private capital needed to commercialize discoveries.
This is especially true in Philadelphia’s area of greatest strength: cell and gene therapy. Unlike many other therapeutic areas, these advanced therapies are extraordinarily capital-intensive. Developing them requires not only years of research and clinical testing but also costly Good Manufacturing Practice (GMP) facilities, specialized talent, and long production timelines.
Without sustained venture investment, companies working in this space often face difficult decisions. They may delay or shelve programs, sell early to larger pharmaceutical players based elsewhere, or relocate key operations to regions with deeper investor pools. Each of those scenarios diminishes the economic return to Philadelphia, even when the science itself originates here.
As GEN pointed out, “venture capital is more than just one category.” It is the difference between a region that creates discoveries and a region that captures the economic rewards of bringing them to market.
Layoffs Underscore the Strain
The effects of Philadelphia’s venture capital shortfall are clear. Over the past year, several local biotech companies have announced layoffs, reflecting both a national funding slowdown and the region’s challenges in attracting investment. From early-stage startups to mid-sized firms, these cuts not only cost jobs but also disrupt research continuity and collaborative networks. While Philadelphia still ranks sixth nationally in life sciences employment with over 88,000 positions, the recent layoffs highlight how quickly progress can be undermined when capital is limited.
Recent Philadelphia Biotech Layoffs
The Risk of Losing Ground
Philadelphia’s seventh-place ranking is not the result of weak science. In fact, by nearly every scientific and infrastructure measure, the region is performing at a level that should position it higher. The challenge is that other regions are pairing science with sustained venture investment.
Los Angeles/Orange County offers a clear example. Until recently, it was seen as a secondary player behind established hubs like Boston, the Bay Area, and San Diego. But a surge of capital has changed its trajectory. Investors, drawn by a critical mass of talent and research institutions, have begun deploying billions into Los Angeles-area companies. That momentum was enough to move the region ahead of Philadelphia this year.
Philadelphia, meanwhile, has already seen some of its homegrown companies expand into Boston or San Francisco to access capital. While many maintain their headquarters here, the economic center of gravity often shifts to where the money is. That trend, if it continues, risks turning Philadelphia into a pipeline of ideas for other hubs to scale and commercialize.
A National Slowdown, A Local Challenge
The funding gap is magnified by broader market conditions. Venture activity nationwide has slowed significantly since the pandemic-era peak, making it harder for all clusters to raise capital. That slowdown puts added pressure on regions like Philadelphia, which already face a comparative disadvantage against Boston and San Francisco’s entrenched ecosystems.
The stakes are high. As GEN noted, Los Angeles’ rise illustrates how quickly momentum can shift when capital aligns with strong science. A region’s place in the rankings is not fixed — it can rise or fall depending on whether investors believe in its potential. For Philadelphia, the concern is that without a stronger capital base, it may miss the window to consolidate its position as the world’s leading cell and gene therapy hub.
The Fundamentals Remain Strong
Despite the slip in rankings, Philadelphia’s fundamentals remain encouraging. The region continues to attract billions in NIH funding, reflecting the quality of its research institutions. Its 16,484 active patent families place it among the nation’s most innovative clusters. Lab space continues to expand, reaching 24.5 million square feet, and its life sciences workforce now exceeds 88,000.
These are not the numbers of a region in decline. They are the numbers of a region with the potential to grow — if the venture capital follows. The challenge is less about science or infrastructure than about aligning financial resources with those strengths.
Looking Ahead
Philadelphia’s drop to seventh place is not catastrophic, but it is a warning. The science is here. The workforce is here. The infrastructure is here. What the region lacks is the one ingredient GEN calls “the fuel that powers biotech growth”: venture capital.
If Philadelphia can find ways to close that gap — by attracting more national investors, nurturing local funds, or building stronger connections between its scientific institutions and the capital markets — it has the potential to climb back up the rankings. If it cannot, the risk is that its breakthroughs will continue to be commercialized elsewhere, with the economic rewards accruing to other hubs.
For now, Philadelphia remains a top-tier cluster with enormous promise. But the 2025 rankings, alongside the wave of biotech layoffs, make clear that science alone is not enough. In biotech, capital — and the stability it provides — decides where the future takes root.
